Hypaque and steroids in the treatment of sudden sensorineural hearing loss.
While the origins of sudden sensorineural hearing loss remain unproven and treatment empirical, the most appropriate therapy remains a matter of controversy. In this paper we have analysed the current forms of treatment, i.e. diatrizoate meglumine, steroids and a vasodilator. The results suggest that although several related factors were shown to indicate a good prognosis regardless of the therapy, none of the currently available regimens produces consistently better results than the spontaneous recovery rate of 65% reported by Mattox & Simmons.
Huang
T S
TS
Department of Otolaryngology, Chang Gung Medical College, Taipei, Taiwan, Republic of China.
Chan
S T
ST
Ho
T L
TL
Su
J L
JL
Lee
F P
FP
D000328:Adult; D001299:Audiometry; D001621:Betahistine / Q000627:therapeutic use*; D003974:Diatrizoate Meglumine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
D011725:Pyridines; D003974:Diatrizoate Meglumine; D011239:Prednisolone; D001621:Betahistine